Blue-green gradient-background.

Varithena Serialization Request

Complete the form below to have your questions answered regarding Varithena serialization.

Your contact information will not be used for any other purpose other than that specified in your information request

*All fields required unless noted below.

Questions or concerns about Varithena?

We're happy to help.

Contact a sales representative.

Have your local Varithena sales representative contact you regarding Varithena.

Contact a representative

Customer care and product complaints.

Communicate questions and complaints about Varithena.

Learn more

By submitting this form, you agree to the privacy policy and terms of use.

Indications

Varithena (polidocanol injectable foam) 1% is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

Important safety information

The use of Varithena is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease. Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately. Varithena can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis. Physicians administering Varithena must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena.

See full prescribing information for Varithena

Varithena is a registered trademark of Boston Scientific. All other trademarks are property of their respective owners.
PI-1263705-AA